Theravance Biopharma clinical trials

Acquired by Zymeworks, Sep 23, 2026 · source ↗

The registry lists 47 studies whose lead sponsor is Theravance Biopharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 5, 2025.

Studies

Recruiting first, then most recently updated. Showing 47 of 47. All Zymeworks studies →

• Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyActive, not recruitingNCT05696717Phase 3

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Phase 4 COPD and Suboptimal Inspiratory Flow RateCompletedNCT05165485Phase 4

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Efficacy and Safety of TD-1473 in Crohn's DiseaseTerminatedNCT03635112Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTerminatedNCT03829657Phase 3

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTerminatedNCT04095793Phase 3

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Efficacy & Safety of TD-1473 in Ulcerative ColitisTerminatedNCT03758443Phase 2/3

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyTerminatedNCT03920254Phase 2/3

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)CompletedNCT02705755Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureCompletedNCT03750552Phase 3

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01458340Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Effect of Inhaled TD-8236 on Allergen-induced Asthmatic ResponseCompletedNCT04150341Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-0903 for ALI Associated With COVID-19CompletedNCT04402866Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Phase 2 Study of TD-9855 to Treat FibromyalgiaCompletedNCT01693692Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary FibrosisTerminatedNCT04589260Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19CompletedNCT04681079

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationCompletedNCT05091723Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.CompletedNCT00674817Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Single Ascending Dose Study of TD-0714 in Healthy SubjectsCompletedNCT02639078Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Succinate Salt Version of GSK961081 for Healthy VolunteersCompletedNCT00550225Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy SubjectsCompletedNCT02663089Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Study of GSK961081 in Healthy Volunteer SubjectsCompletedNCT00887406Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy VolunteersCompletedNCT00687700Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-1473 for Active Ulcerative Colitis (UC)CompletedNCT02818686Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Single and Multiple Ascending Dose Study of TD-8236 by InhalationCompletedNCT03652038Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855CompletedNCT04200573Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19CompletedNCT04350736Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Thorough QT Study to Evaluate Ampreloxetine in Healthy SubjectsCompletedNCT04688632Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Single Dose Bioavailability and Ethnobridging PK Study in Healthy SubjectsCompletedNCT04587713Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly SubjectsCompletedNCT02954263Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-1792 in Gram-positive Complicated Skin and Skin Structure InfectionCompletedNCT00442832Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy SubjectsCompletedNCT02657122Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-9855 Mass Balance StudyCompletedNCT01924143Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Single Ascending Dose Study of TD-1439 in Healthy SubjectsCompletedNCT02903095Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-1607 SAD Study in Healthy SubjectsCompletedNCT01791049Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-1607 MAD Study in Healthy SubjectsCompletedNCT01949103Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-6450 MAD Study in HCV Infected SubjectsCompletedNCT02116543Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly SubjectsCompletedNCT02709928Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)CompletedNCT03103412Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Multiple Dose Ethnobridging PK Study in Healthy SubjectsCompletedNCT03750565Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Single and Multiple Ascending Dose, First-in- Human Study in Healthy SubjectsCompletedNCT04044339Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging StudyCompletedNCT03555617Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsCompletedNCT03408470Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• TD-6450 SAD and MAD in Healthy SubjectsCompletedNCT02022306Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Drug-Drug Interaction (DDI) Study for TD-9855CompletedNCT03432793Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) StudyCompletedNCT02267525Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• Phase 2 Study of Velusetrag in Diabetic or Idiopathic GastroparesisCompletedNCT01718938Phase 2

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks

• A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy SubjectsTerminatedNCT01644240Phase 1

  Sponsor listed in the registry: Theravance Biopharma · First submitted before Theravance Biopharma became part of Zymeworks